Maximizing cost-effectiveness by conjugating modifications for clinical application of innovative nucleic acid drugs

Principal Investigator	Department of Medical Data Science, Graduate School of Medicine, The University of Osaka
	Professor Hideshi ISHII

Project Outline

- This project targets refractory gastrointestinal cancers that do not respond to conventional treatments.
- We are developing nucleic acid drugs as a part of an advanced seed project at The University of Osaka.
- Nucleic acid drugs have attracted attention for their potential for precise control.
- This project targets cancer stem cells and their microenvironments with nucleic acid drugs.
- Basic nonclinical testing is already underway, and patenting is complete.
- Development is expected to accelerate under cooperation with drug manufacturers.

■Strategy:

"Differentiation" is the key to success in the global anticancer drugs market, which is expected to reach 500 billion dollars in 2020.

This seed project of ours represents a worldfirst concept.

In addition, we use a special method for optimizing clinical applications.

We have patented this basic seed and are building on our success.



**The world's first conjugate-modified nucleic acid drug for treating cancer.
The pinpoint attack surpasses existing treatments,
using a strategy that matches the tumors' microenvironments.
Basic preclinical tests completed.**